Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Vanguard Group Inc. lessened its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,010,544 shares of the biopharmaceutical company’s stock after selling 41,145 shares during the quarter. Vanguard Group Inc. owned about 4.09% of Theravance Biopharma worth $18,919,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Jane Street Group LLC increased its position in Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 1,640 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock worth $2,766,000 after acquiring an additional 2,060 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Theravance Biopharma by 21.1% in the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,349 shares during the last quarter. XTX Topco Ltd raised its position in shares of Theravance Biopharma by 34.5% in the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 5,243 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Theravance Biopharma in the 4th quarter worth about $69,000. Institutional investors own 99.10% of the company’s stock.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.33.

Theravance Biopharma Price Performance

TBPH stock opened at $8.60 on Thursday. The stock has a market capitalization of $425.45 million, a P/E ratio of -8.51 and a beta of 0.14. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.90. The business has a fifty day moving average price of $9.12 and a 200-day moving average price of $9.14.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. As a group, analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.